Focused On-demand Library for Homeobox protein Hox-A13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P31271

UPID:

HXA13_HUMAN

Alternative names:

Homeobox protein Hox-1J

Alternative UPACC:

P31271; A4D188; O43371

Background:

The Homeobox protein Hox-A13, also known as Homeobox protein Hox-1J, plays a pivotal role in the developmental regulatory system. It functions as a sequence-specific, AT-rich binding transcription factor, providing cells with specific positional identities along the anterior-posterior axis. This protein's intricate involvement in developmental processes underscores its significance in cellular biology.

Therapeutic significance:

Homeobox protein Hox-A13 is implicated in Hand-foot-genital syndrome and Guttmacher syndrome, both of which involve limb and genitourinary anomalies. Understanding the role of Homeobox protein Hox-A13 could open doors to potential therapeutic strategies for these congenital disorders, highlighting the importance of targeted research in this area.